Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- VZ +4.6%, CLF +3.7%, DPZ +3.1%, ROP +1%
Other news:
- SQNS +12.2% (announced the acquisition of an additional 1,264 bitcoin for ~$150 million at an average price inclusive of fees of ~$118,659 per bitcoin)
- LX +10.8% (announces $50 million share repurchase program and management purchase)
- ORKA +7.3% (IND clearance for EVERLAST-A phase 2a trial of ORKA-001 in psoriasis with Phase 1 data to be presented at EADV in September)
- CNL +6.6% (Drills 442.35 Metres at 2.16 g/t Gold Equivalent Commencing from Surface at Apollo)
- GLUE +6.2% (First Subjects Dosed in Phase 1 Study of MRT-8102)
- FFAI +5.7% (Faraday X Unveils Two Groundbreaking Global-First Products Along with a Transformative Technology Architecture in Los Angeles on July 17)
- AUTL +4.6% (CAR T Therapy AUCATZYL (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia)
- ALKS +2.7% (topline results from Vibrance-1 Phase 2 Study of once-daily Alixorexton)
- CRGO +2.6% (SriLankan Cargo has partnered with WebCargo for online air cargo booking and payments)
- CGEN +2.6% (First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer)
- TRI +2.5% (to join the Nasdaq-100 Index beginning July 28)
- LAES +1.9% (SEALSQ Corp and WISeKey (WKEY) confirm new cross-border center of excellence for the 4th Industrial Revolution activated between La Line and Gibraltar)
- LYEL +1.7% (files for 625,000 share common stock offering by selling shareholders)
- QTRX +1.5% (mgmt committed to a plan to terminate certain executives of the newly acquired subsidiary, Akoya Biosciences)
- DNN +1.4% (Announces Additional High-Grade Uranium Mineralization Discovered at McClean South)
- RUN +1% (prices $431 million senior securitization of residential solar systems)